Allergy immunotherapy: the future of allergy treatment.
Allergic respiratory disease represents a significant and expanding health problem worldwide. Allergic symptoms, such as asthma and hay fever, cause sleep impairment and reduce school and work performance. The cost to society is substantial. Allergen avoidance and pharmacotherapy cannot control the disease. Only allergy immunotherapy has disease-modifying potential and should be included in optimal treatment strategies. Allergy immunotherapy was first administered as subcutaneous injections and has been practiced for the past 100 years or so. Recently, tablet-based sublingual allergy immunotherapy (SLIT) was introduced with comprehensive clinical documentation. SLIT tablets represent a more patient-friendly concept because they can be used for self-treatment at home.
ALK A/S, Bøge Allé 1, DK-2970 Hørsholm, Denmark. Electronic address: jnldk@alk.net.
Jørgen Nedergaard
JN
Larsen
ALK A/S, Bøge Allé 1, DK-2970 Hørsholm, Denmark.
Louise
L
Broge
ALK A/S, Bøge Allé 1, DK-2970 Hørsholm, Denmark.
Henrik
H
Jacobi
D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D003365:Costs and Cost Analysis; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000276:immunology
D000485:Allergens